In this issue:
Low-dose CT screening for lung cancer in NZ
Osimertinib in resected EGFR-mutated NSCLC
Lung-cancer treatment advances and population mortality
Geographic variation in mortality among NSCLC patients
Exercise for people with lung cancer
Durvalumab plus chemotherapy in mesothelioma
Carboplatin/etoposide vs topotecan in SCLC
Sotorasib in advanced solid tumours
Pembrolizumab in ECOG PS2 NSCLC patients
First-line atezolizumab for PDL-1 NSCLC
Please login below to download this issue (PDF)